Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

Journal of Clinical Oncology

Volumn 31, Issue 36, 2013, Pages 4529-4535

  Kapoor, Prashant ^a   Kumar, Shaji K ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Buadi, Francis ^a   Dingli, David ^a   Russell, Stephen J ^a   Hayman, Suzanne R ^a   Witzig, Thomas E ^a   Lust, John A ^a   Leung, Nelson ^a   Lin, Yi ^a   Zeldenrust, Steven R ^a   McCurdy, Arleigh ^a   Greipp, Philip R ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CREATININE BLOOD LEVEL; CYTOGENETICS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84894459968     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.0086     Document Type: Article

References (40)

1. Barlogie B, Tricot GJ, van Rhee F, et al: Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J of Haematol 135:158-164, 2006 (Pubitemid 44401612)
2. Hari P, Pasquini MC, Vesole DH: Cure of multiple myeloma: More hype, less reality. Bone Marrow Transplant 37:1-18, 2006 (Pubitemid 43135309)
3. Mehta J, Singhal S: High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 40:1101-1114, 2007 (Pubitemid 350193802)
4. Rajkumar SV: Treatment of myeloma: Cure vs control. Mayo Clin Proc 83:1142-1145, 2008
5. Sirohi B, Powles R: International myeloma grand round. Lancet Oncol 2:571-579, 2001 (Pubitemid 33586870)
6. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
7. Usmani SZ, Crowley J, Hoering A, et al: Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: Are patients now being cured? Leukemia 27:226-232, 2013
8. Ladetto M, Pagliano G, Ferrero S, et al: Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28:2077-2084, 2010
9. Paiva B, Martinez-Lopez J, Vidriales MB, et al: Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 29:1627-1633, 2011
10. Alexanian R, Delasalle K, Wang M, et al: Curability of multiple myeloma. Bone Marrow Res 2012:916479, 2012
11. Cavo M, Tosi P, Zamagni E, et al: Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25: 2434-2441, 2007 (Pubitemid 46999214)
12. Chanan-Khan AA, Giralt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28:2612-2624, 2010
13. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218, 2007 (Pubitemid 47516593)
14. Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Upfront or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136, 1998 (Pubitemid 28492319)
15. Kumar SK, Dingli D, Lacy MQ, et al: Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Br J Haematol 141:205-211, 2008 (Pubitemid 351406221)
16. Tricot G, Reiner M, Sawyer J, et al: A complete remission (CR) is not a prerequisite for prolonged survival after autotransplants for multiple myeloma. Blood 104, 2004 (abstr 926)
17. Dingli D, Pacheco JM, Nowakowski GS, et al: Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 25:4933-4937, 2007 (Pubitemid 350220425)
18. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998 (Pubitemid 28435189)
19. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215-224, 2009
20. Greipp PR, Kumar S: Plasma cell labeling index. Methods Mol Med 113:25-35, 2005
21. Kaplan E: MP: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457- 481, 1958
22. Rajkumar SV, Harousseau JL, Durie B, et al: Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel Blood 117: 4691-4695, 2011
23. Kumar SK, Lacy MQ, Dispenzieri A, et al: Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 118:1585-1592, 2012
24. Gay F, Larocca A, Wijermans P, et al: Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients. Blood 117: 3025-3031, 2011
25. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822-824, 1983 (Pubitemid 13013370)
26. Cunningham D, Paz-Ares L, Milan S, et al: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759-763, 1994 (Pubitemid 24110915)
27. Barlogie B, van Rhee F, Shaughnessy JD Jr, et al: Making progress in treating multiple myeloma with total therapies: Issue of complete remission and more. Leukemia 22:1633-1636, 2008
28. Lahuerta JJ, Mateos MV, Martínez-LópezJ, et al: Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26:5775-5782, 2008
29. Harousseau JL, Palumbo A, Richardson PG, et al: Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalanprednisone versus melphalan-prednisone. Blood 116: 3743-3750, 2010
30. Dispenzieri A, Zhang L, Katzmann JA, et al: Appraisal of immunoglobulin free light chain as a marker of response. Blood 111:4908-4915, 2008
31. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629, 2010
32. Moreau P, Avet-Loiseau H, Facon T, et al: Bortezomib plus dexamethasone versus reduceddose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752-5758, 2011
33. van de Velde HJ, Liu X, Chen G, et al: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92:1399-1406, 2007 (Pubitemid 350144158)
34. Martinez-Lopez J, Blade J, Mateos MV, et al: Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529-534, 2011
35. Barlogie B, Hall R, Zander A, et al: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298-1301, 1986 (Pubitemid 16080597)
36. Kyle RA, Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:3-9, 2009
37. Paiva B, Vidriales MB, Cerveró J, et al: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017-4023, 2008
38. Zhan F, Barlogie B, Arzoumanian V, et al: Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109:1692-1700, 2007 (Pubitemid 46239604)
39. Barlogie B, Anaissie E, Haessler J, et al: Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113:355-359, 2008
40. Hoering A, Crowley J, Shaughnessy JD Jr, et al: Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 114:1299-1305, 2009